1.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022;40(11):1358-1373.e8. doi:10.1016/j.ccell.2022.10.017.
1.
Bustoros M, Anand S, Sklavenitis-Pistofidis R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13(1):3449. doi:10.1038/s41467-022-30694-w.
1.
Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679. doi:10.1371/journal.pgen.1007679.
1.
Xu JZ, Garrett ME, Soldano KL, et al. Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. Am J Hematol. 2018;93(12):1451-1460. doi:10.1002/ajh.25263.
1.
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481-487. doi:10.1038/nature21029.
1.
Hacken ET, Guièze R, Wu CJ. SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell. 2017;32(5):716-716.e1. doi:10.1016/j.ccell.2017.10.015.
1.
Deming Y, Li Z, Kapoor M, et al. Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers. Acta Neuropathol. 2017;133(5):839-856. doi:10.1007/s00401-017-1685-y.
1.
Hebert JD, Myers SA, Naba A, et al. Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches. Cancer Res. 2020;80(7):1475-1485. doi:10.1158/0008-5472.CAN-19-2961.
1.
Oudin MJ, Weaver VM. Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harb Symp Quant Biol. 2016;81:189-205. doi:10.1101/sqb.2016.81.030817.
1.
Sheahan AV, Ellis L. Epigenetic reprogramming: A key mechanism driving therapeutic resistance. Urol Oncol. 2018;36(8):375-379. doi:10.1016/j.urolonc.2017.12.021.